Video

Dr. Matulewicz discusses underreported smoking status in GU cancer trials

Author(s):

Urology Times staff
Conference|AUA: Prostate Cancer

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      In this video, Richard Matulewicz, MD, MS, explains potential factors in underreported smoking status for GU cancer patients in clinical trials. Matulewicz is an assistant professor in the department of urology at Memorial Sloan Kettering Cancer Center, New York City.

      Related Videos
      Joy Maulik, CRNP, on the importance of genetic testing in prostate cancer
      Joy Maulik, CRNP, on the importance of genetic testing in prostate cancer
      5 key trial insights from AUA 2025
      5 key trial insights from AUA 2025
      Shot of a doctor showing a patient some information on a digital tablet | Image Credit: © - bongkarn - stock.adobe.com
      Experts discuss expanding use of vibegron for OAB
      John Michael DiBianco, MD, answers a question during a Zoom video interview
      John Michael DiBianco, MD, on silicone vs polyurethane stents for patients with kidney stones
      Félix Guerrero-Ramos, MD, on TAR-200 in papillary disease-only NMIBC
      Félix Guerrero-Ramos, MD, on TAR-200 in papillary disease-only NMIBC
      Khurshid Ghani, MD, on trial of stent omission following ureteroscopy
      Khurshid Ghani, MD, on trial of stent omission following ureteroscopy
      Karyn S. Eilber, MD, answers a question during a Zoom video interview
      Karyn S. Eilber, MD, shares her reaction to genitourinary syndrome of menopause guidelines
      Man talking with a doctor | Image Credit: © Pcess609 - stock.adobe.com
      Expert discusses the relationship between RCTs and real-world efficacy of prostate cancer treatments
      Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
      Endourologist discusses shared decision-making and laser lithotripsy
      Shreyas Joshi, MD, recaps AUA session on chemotherapy vs novel NMIBC options
      Shreyas Joshi, MD, recaps AUA session on chemotherapy vs novel NMIBC options
      Related Content
      Welcome to fabulous Las vegas Nevada sign with blur strip road b | Image Credit: © littlestocker - stock.adobe.com
      May 5th 2025

      AUA 2025 recap: Urologic oncology trials in progress

      Hannah Clarke
      Take a look through some of the notable studies that were spotlighted during this year’s meeting.
      Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25
      May 4th 2025

      Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25

      Amy M. Pearlman, MD Kevin C. Zorn, MD, FRCSC, FACS
      Urologists discuss innovative BPH treatments, emphasizing personalized care, and the importance of ejaculatory preservation.
      TAR-200 elicits high complete response rate in BCG-unresponsive NMIBC
      May 2nd 2025

      TAR-200 elicits high complete response rate in BCG-unresponsive NMIBC

      Hannah Clarke
      Data showed an overall CR rate of 82.4%.
      Pearls & Perspectives: Future of reconstructive urology, with Ryan Terlecki, MD, at AUA 2025
      April 30th 2025

      Pearls & Perspectives: Future of reconstructive urology, with Ryan Terlecki, MD, at AUA 2025

      Amy M. Pearlman, MD Ryan Terlecki, MD
      A discussion on evolution of surgical education, importance of video training, and the future of patient-centered care in reconstruction.
      TAR-200 boasts impressive DFS rates in papillary disease-only NMIBC
      April 30th 2025

      TAR-200 boasts impressive DFS rates in papillary disease-only NMIBC

      Hannah Clarke
      Data showed a disease-free survival rate of 85.3% at 6 months and 81.1% at 9 months.
      Man talking with a doctor | Image Credit: © Pcess609 - stock.adobe.com
      Published: April 29th 2025 | Updated: April 29th 2025

      Ultra-low PSA responses are more prevalent with darolutamide plus ADT

      Benjamin P. Saylor
      The investigators reported that ultra-low PSA responses “were associated with prolonged rPFS and delayed progression to mCRPC and PSA progression.”
      © 2025 MJH Life Sciences

      All rights reserved.